

YOUNG WILLIAM
Form 4
September 29, 2011

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
YOUNG WILLIAM

2. Issuer Name and Ticker or Trading Symbol
BIOGEN IDEC INC. [BIIB]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)

Director 10% Owner
 Officer (give title below) Other (specify below)

BIOGEN IDEC INC., 133 BOSTON POST ROAD

09/27/2011

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person
 Form filed by More than One Reporting Person

WESTON, MA 02493

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired or Disposed of (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)			
				(A) or (D)	Price					
Common Stock	09/27/2011		M ⁽¹⁾	V	12,500	A	\$ 47.55	39,359	D	
Common Stock	09/27/2011		M ⁽¹⁾	V	3,125	A	\$ 46.99	42,484	D	
Common Stock	09/27/2011		M ⁽¹⁾	V	5,950	A	\$ 52.22	48,434	D	
Common Stock	09/27/2011		M ⁽¹⁾	V	5,700	A	\$ 59.17	54,134	D	
Common Stock	09/27/2011		M ⁽¹⁾	V	5,975	A	\$ 53.43	60,109	D	

Edgar Filing: YOUNG WILLIAM - Form 4

Common Stock 09/27/2011 S⁽¹⁾ 33,250 D \$ 96.14 26,859 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)				
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share
Stock Option (Right to Buy) ⁽²⁾	\$ 47.55	09/27/2011		M ⁽¹⁾		12,500		⁽³⁾	01/09/2016	Common Stock	12,500
Employee Stock Option (Right to Buy) ⁽²⁾	\$ 46.99	09/27/2011		M ⁽¹⁾		3,125		⁽⁴⁾	05/24/2016	Common Stock	3,125
Stock Option (Right to Buy)	\$ 52.22	09/27/2011		M ⁽¹⁾		5,950		⁽⁵⁾	05/30/2017	Common Stock	5,950
Stock Option (Right to Buy)	\$ 59.17	09/27/2011		M ⁽¹⁾		5,700		06/19/2009	06/18/2018	Common Stock	5,700
Stock Option (Right to Buy) ⁽²⁾	\$ 53.43	09/27/2011		M ⁽¹⁾		5,975		06/03/2010	06/02/2019	Common Stock	5,975

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
YOUNG WILLIAM BIOGEN IDEC INC. 133 BOSTON POST ROAD WESTON, MA 02493		X		

Signatures

Aras Lapinskas, Attorney in Fact for William D. Young	09/29/2011
<small>**Signature of Reporting Person</small>	<small>Date</small>

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities and Exchange Act of 1934.
- (2) Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC Rule 16(b)-3(d).
- (3) Immediately exercisable for all the option shares on grant date of 01/09/2006 subject to Issuer's repurchase rights which lapse on 01/09/2007.
- (4) Options will vest in their entirety on 05/25/2007 provided that the Reporting Owner is then a member of the Issuer's Board of Directors.
- (5) Options will become 100% exercisable upon completion of one year of service with Biogen Idec Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.